Department of Exptl. Med., II University of Naples, S. Andrea delle Dame, 7, 80138 Naples, Italy.
Behav Brain Res. 2010 Jun 26;210(1):99-106. doi: 10.1016/j.bbr.2010.02.020. Epub 2010 Feb 13.
The psychostimulant methylphenidate and the non-stimulant atomoxetine are two approved drugs for attention-deficit hyperactivity disorder (ADHD) therapy. The aim of this study was to investigate the long-term effects of prepuberal subchronic methylphenidate and atomoxetine on adult behaviour and the forebrain neurotransmitter and metabolite content of Naples High-Excitability (NHE) rats, a genetic model for the mesocortical variant of ADHD. Male NHE rats were given a daily intraperitoneal injection (1.0mg/kg) of methylphenidate, atomoxetine or vehicle from postnatal day 29 to 42. At postnatal day 70-75, rats were exposed to spatial novelty in the Làt and radial (Olton) mazes. Behavioural analysis for indices of horizontal, vertical, non-selective (NSA) and selective spatial attention (SSA) indicated that only methylphenidate significantly reduced horizontal activity to a different extent, i.e., 39 and 16% respectively. Moreover methylphenidate increased NSA as assessed by higher leaning duration. The high-performance liquid chromatography (HPLC) tissue content assessment of dopamine, norepinephrine, serotonin and relative metabolites in the prefrontal cortex (PFC), cortical motor area (MC), dorsal striatum (DS), ventral striatum (VS), hippocampus and mesencephalon indicated that methylphenidate decreased (i) dopamine, DOPAC, norepinephrine, MHPG, 5-HT and 5-HIAA in the PFC, (ii) dopamine, DOPAC, HVA, serotonin, 5-HIAA in the DS, (iii) dopamine, DOPAC, HVA and MHPG (but increased norepinephrine) in the VS and (iv) norepinephrine, MHPG, serotonin and 5-HIAA in the hippocampus. Atomoxetine increased dopamine and decreased MHPG in the PFC. Like methylphenidate, atomoxetine decreased dopamine, DOPAC, HVA, serotonin and 5-HIAA in the DS, but decreased MHPG in the VS. These results suggest that methylphenidate determined long-term effects on behavioural and neurochemical parameters, whereas atomoxetine affected only the latter.
哌甲酯和阿托西汀是两种被批准用于治疗注意力缺陷多动障碍(ADHD)的药物。本研究旨在探讨青春期前亚慢性哌甲酯和阿托西汀对纳波利高兴奋(NHE)大鼠(ADHD 中隔核变异的遗传模型)成年行为和前脑神经递质和代谢物含量的长期影响。雄性 NHE 大鼠从出生后第 29 天至 42 天每天接受腹膜内注射(1.0mg/kg)哌甲酯、阿托西汀或载体。在出生后第 70-75 天,大鼠在 Làt 和放射状(Olton)迷宫中暴露于空间新奇性。行为分析水平、垂直、非选择性(NSA)和选择性空间注意力(SSA)的指标表明,只有哌甲酯在不同程度上显著降低了水平活动,即分别为 39%和 16%。此外,哌甲酯通过增加倾斜持续时间增加了 NSA。高效液相色谱(HPLC)组织中前额叶皮层(PFC)、皮质运动区(MC)、背侧纹状体(DS)、腹侧纹状体(VS)、海马和中脑多巴胺、去甲肾上腺素、血清素和相对代谢物的含量评估表明,哌甲酯降低了(i)PFC 中的多巴胺、DOPAC、去甲肾上腺素、MHPG、5-HT 和 5-HIAA,(ii)DS 中的多巴胺、DOPAC、HVA、血清素、5-HIAA,(iii)VS 中的多巴胺、DOPAC、HVA 和 MHPG(但增加去甲肾上腺素)和(iv)海马中的去甲肾上腺素、MHPG、血清素和 5-HIAA。阿托西汀增加了 PFC 中的多巴胺并降低了 MHPG。与哌甲酯一样,阿托西汀降低了 DS 中的多巴胺、DOPAC、HVA、血清素和 5-HIAA,但降低了 VS 中的 MHPG。这些结果表明,哌甲酯确定了对行为和神经化学参数的长期影响,而阿托西汀仅影响后者。